Canada announces new, strengthened partnership with the European Union
BRUSSELS, Belgium, /CNW/ - Today, the Prime Minister, Mark Carney, announced an historic step forward for Canada's relationship with the European Union (EU). Together with President Costa and President von der Leyen, the Prime Minister announced they will forge a new, ambitious, and comprehensive partnership. The New EU-Canada Strategic Partnership of the Future is rooted in shared values and the rules-based international system, and strategically aimed to pursue common interests.
Canada and the EU will soon launch comprehensive negotiations across multiple areas to strengthen co-operation and connection – including trade and economic security, the digital transition, and the fight against climate change and environmental degradation. This will create more economic opportunities and long-term prosperity for workers, businesses, and citizens in both Canada and the EU.
As part of this new, strengthened relationship, Canada and the EU today signed the Security and Defence Partnership, which provides a framework for dialogue and co-operation in security and defence priorities. For Canada and the EU Member States who are NATO Allies, this will also help deliver on capability targets more quickly and economically. This new partnership is the intentional first step toward Canada's participation in Security Action for Europe (SAFE), an instrument of the ReArm Europe Plan/Readiness 2030. Canada's participation in this initiative will create significant defence procurement and industrial opportunities for Canada.
In an increasingly dangerous and divided world, Canada's new government is focused on strengthening and diversifying our international partnerships. We will work with the EU and other allies to build a new international, rules-based system for a more secure and prosperous world.
Quote
"Canada's new government has a mandate to diversify and strengthen international partnerships. To that end, we took an historic step forward today to deepen Canada's relationship with the European Union. Through increased co-operation in defence, trade, and commerce, we'll create greater prosperity, security, and stability on both sides of the Atlantic."
— The Rt. Hon. , Prime Minister of Canada
Quick Facts
While in Belgium, Prime Minister Carney also met with the Prime Minister of Belgium, Bart De Wever, to strengthen bilateral ties and advance common priorities. The two leaders visited the Antwerp Schoonselhof Military Cemetery to pay tribute to Canadian Armed Forces members who lost their lives during the First and Second World Wars.
Unveiled earlier this year, the ReArm Europe Plan/Readiness 2030 is the European Commission's plan to boost defence funding in Europe, including through Security Action for Europe (SAFE) loans. This initiative provides up to €150 billion in loans to EU Member States, members of the EU single market, and Ukraine to support defence investments, with a focus on joint procurement projects.
Canada and the European Union
This document is also available at https://pm.gc.ca
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
27 minutes ago
- Winnipeg Free Press
Serbian police remove street blockades in Belgrade and make new arrests as tensions persist
BELGRADE, Serbia (AP) — Serbian police removed street blockades in the capital Belgrade early Monday that were set up as part of a protest over a spate of arrests of anti-government protesters after a massive rally demanding an early parliamentary election. Thousands of demonstrators placed metal fences and garbage containers at various locations in Belgrade and elsewhere throughout the country Sunday evening, including a key bridge over the Sava River in the capital. Protesters say they plan to return Monday. Police said in a statement that a number of people have been detained without specifying how many. Video posted on social media showed police vehicles driving at high speed through a blockade in one Belgrade street and people fleeing in panic. The blockades are part of persistent dissent against the government of populist President Aleksandar Vucic that started after a train station canopy crashed in the country's north, killing 16 people. Protesters have demanded justice for the victims of the canopy collapse in Novi Sad on Nov. 1, which many in Serbia blame on corruption-fueled negligence in state infrastructure projects. Tens of thousands of people gathered Saturday at a student-led protest in Belgrade to call for the snap vote they hope will oust Vucic's right-wing government. Groups of protesters clashed with police after the official part of the rally ended. Dozens were later detained. Vucic has refused to call the election, which is scheduled to be held in 2027. University students and professors are a key force behind nearly eight months of almost daily protests and Vucic has accused them of 'terror' and attempts to destroy the country. Nearly 50 officers and 22 protesters were injured in clashes late Saturday. Riot police used batons, pepper spray and shields to charge at demonstrators who threw rocks and other objects at police cordons. Nearly 40 people face criminal charges over the clashes, police said. Authorities also have detained at least eight university students for alleged acts against constitutional order and security, accusing them of planning attacks on state institutions. Protesters have demanded their immediate release. Critics say Vucic has become increasingly authoritarian since coming to power over a decade ago, stifling democratic freedoms while allowing corruption and organized crime to flourish, which he has denied. Serbia is formally seeking entry to the European Union, but Vucic's government has nourished relations with Russia and China.
Canada News.Net
an hour ago
- Canada News.Net
Access to Nature Shouldn't Be a Privilege
In Canadian politics, few ideas cut across party lines as cleanly as how much we love nature. Policies on protecting our environment-and opinions about what harms it-vary widely. But you can bet that any campaign ad, throne speech or holiday message is likely to include a reference to the Maple Leaf along with the Rocky Mountains, our prairies and forests, the Great Lakes, our coastlines or the High Arctic. Nature is used as a kind of shorthand for who we are and what we value, writes Mathieu Roy for Policy Options. But, he adds, when a new government puts that belief as a core item in its agenda, as Prime Minister Mark Carney's Liberals appear to have done, we must ask: What does it mean to say nature is central to Canadian identity and what would it take to translate that into reality? This is not just a philosophical question. It's a call to action. If we take the claim seriously-and we should-it carries at least three practical obligations: expanding access to nature for all Canadians, protecting more of the land that defines us, and building natural infrastructure, like parks and trails, to connect us to nature-and each other. Most Canadians agree that nature is part of who we are, as evidenced in a recent poll by EKOS, a public-opinion research firm. But for many, being able to enjoy nature daily is limited or out of reach. Urbanization, neighbourhoods with few parks, trails that can only be reached easily with a car and the rising cost of living make it harder for people to experience the physical and mental benefits of time spent outdoors. If nature is a core part of our identity, access to it shouldn't be a privilege. It should be a right. That means investing in public spaces that bring nature closer to where people live, including more green spaces, trails and community-led outdoor programming. Such funding is fundamental to fostering a deeper connection with nature, promoting belonging, improving health and supporting local culture. To protect nature-a pillar of the Liberal campaign platform in the April election-we need more than regulations. Under a global biodiversity framework agreed to in 2022 at the COP15 conference in Montreal, Canada has committed to increasing access to green spaces (forests, parks and agricultural land) and blue spaces (lakes, rivers and wetlands), especially in urban areas. It has also promised to integrate nature into how we live plan and build. This target recognizes that people need to care about nature to protect it and are more likely to do so when nature is a part of their everyday lives. No government can achieve this goal alone. Partnerships with Indigenous communities, non-profit organizations and local experts play an important role in supporting a connection to nature and making conservation a mainstream, dinner-table subject. We need to build natural infrastructure that reflects who we are and what we care about. Prioritizing the country's network of trails is a strong example. They support low-carbon transportation, protect green spaces, act as firebreaks during climate emergencies, provide corridors for wildlife and stimulate local economies. These aren't soft benefits. They are measurable returns on public investment and serve to anchor nature in our daily lives. The ecological benefits of the Trans Canada Trail are valued at an estimated $82 million annually. On top of that are the health benefits for the 2.6 million Canadian adults who use it, estimated to save $1.7 billion in health-care costs. Too often treated as an afterthought, this kind of infrastructure unites a country and reflects public values. It deserves centre stage in our national vision. National parks systems, trail networks or innovative public transportation routes all illustrate how shared infrastructure can transcend utility and become a source of collective pride. The Carney government has an opportunity to lead on this front by championing projects that not only connect Canadians but embody our shared values and reflect our deep connection to the land. Investing in the relationship between people and nature is one of the most powerful and unifying choices the new government can make if it wants to fulfil its promise to protect the environment, grow our economy and embrace our national identity. That means going beyond a mention of the Maple Leaf during question period. It means working to embed nature into the lives of Canadians through improved access, robust protection and sustainable development.
Cision Canada
an hour ago
- Cision Canada
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site. Both facilities undergoing expansions are essential components of Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company's commitment to delivering innovative solutions that align with patient needs. Piramal Pharma celebrated the groundbreaking of the expansion of its sterile injectables development and manufacturing facility on June 25, 2025. MUMBAI, India, June 30, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), recently announced a $90M investment plan to expand two of its U.S. facilities, which are critical to its integrated offering. This ambitious investment underscores the company's commitment to industry leadership through continuous growth and innovation. The two sites involved in the expansion are: Riverview, Michigan: The Riverview site provides comprehensive drug substance development and manufacturing services, including specialized solutions for high potency APIs (HPAPIs). This facility is a vital element of ADCelerate™, supplying the payload-linkers essential to the overall safety, stability, and efficacy of ADC therapies. The expansion will add a commercial-scale suite specifically designed for the development and manufacturing of payload-linkers, which is expected to be operational by the end of 2025. Lexington, Kentucky: The Lexington site is Piramal Pharma's dedicated fill/finish facility, specializing in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. As a critical component of Piramal Pharma's integration, the site provides fill/finish services for all integrated programs, including ADCelerate™ projects. The expansion will add commercial-scale sterile injectable manufacturing capabilities with 24,000 additional square feet of manufacturing space, a new laboratory, and state-of-the-art machinery, including a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer. The expansion is expected to be completed by late 2027. Piramal Pharma recently broke ground on the expansion plan for its Lexington, Kentucky facility. To celebrate this important milestone and the future growth it signifies for the company, Piramal Pharma hosted a groundbreaking ceremony at the facility on June 25, 2025. This investment comes at a pivotal moment for the sterile injectables market, which is experiencing significant growth driven by increased medical necessity, broader regulatory approvals, and sizable advancements in scientific research and development. Additionally, the streamlined delivery systems associated with sterile injectables contribute to their efficacy and safety, making these solutions increasingly popular among both healthcare providers and patients. Similarly, ADC therapies are gaining substantial traction, fueled by ongoing innovation, wider regulatory acceptance, and robust evidence demonstrating their effectiveness. The growing prevalence of ADCs underscores the pressing need for expanded manufacturing and development capabilities to meet the evolving landscape of patient care. This investment positions Piramal Pharma to capitalize on these trends, ensuring the company can meet the rising demand for both sterile injectables and ADC therapies while enhancing its competitive edge in the market. Upon completion of the expansion in late 2027, the Lexington site will more than double its manufacturing capacity, increasing from 104 product batches per year (at peak utilization) to over 240 annual batches. "We prioritize patient, consumer, and customer centricity in all our operations, engaging with the populations we serve to better understand, anticipate, and address their needs. Our research has revealed that the sterile injectables market is projected to exceed $20B by 2028, underscoring the urgent need for us to enhance our offerings in this segment. We are confident that this strategic $90M investment will empower us to meet the demands of this market, reinforcing our position as a trusted global partner in biologic manufacturing. By enhancing the services we provide to our partners, we can reduce the burden of disease for more patients around the globe," said Nandini Piramal, Chairperson, Piramal Pharma. "As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements," said Peter DeYoung, Chief Executive Officer, Piramal Global Pharma. "ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumors. As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate™, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide." The Lexington facility expansion also represents an investment in the local community, creating 40 new full-time jobs that will enhance the local economy and strengthen Piramal Pharma's workforce. Piramal Pharma will continue to work alongside local partners, leveraging the region's strengths to remain at the forefront of innovation. Additionally, this investment aligns with the growing trend toward U.S. onshore manufacturing, reinforcing the company's dedication to domestic production in the U.S. and supply chain resilience. At the groundbreaking ceremony, Lexington Mayor Linda Gorton expressed her excitement about the project and the promising opportunities it presents for the city, stating, "Piramal's decision to expand its facility here in Lexington sends a message around the world that Lexington is a great place to do business. Lexington is home to one of the nation's best pharmacy programs – the University of Kentucky College of Pharmacy – and we are well on our way to becoming a leader in the pharmaceutical industry, as well." Others echoed Mayor Gorton's sentiment with equal enthusiasm, including Jim Stephanou, CEO of IPS-Integrated Project Services, who said, "IPS is a proud supporter of Piramal's growth over the past five years, providing fit-for-purpose solutions on transformative projects across India, the UK, Canada, and the U.S. Our longstanding relationship is built on trust and a relentless commitment to technical excellence. Nothing is more rewarding than seeing shovels in the ground, especially here in Lexington. This groundbreaking highlights our deep expertise in Aseptic Fill/Finish facilities, and our passion to help Piramal bring this advanced manufacturing facility to life to deliver critical therapies to patients around the world." Commerce Lexington President and CEO, Bob Quick, said, "We are proud to celebrate this milestone moment with Piramal and excited for its continued growth and success. Biotech is a key strategic target for Greater Lexington economic development professionals, and this expansion will further strengthen the region as a hub for biotech and life sciences. Piramal's investment highlights the advantages of the area as an exceptional place where innovative companies come to grow and thrive." Piramal Pharma Solutions' $90M investment in its U.S. facilities represents a significant advancement in its manufacturing capabilities and underscores its ongoing commitment to patient-centric care. This strategic move will enable Piramal Pharma to meet the evolving needs of the healthcare landscape, positioning the company at the forefront of the rapidly growing sterile injectables and ADC markets and ensuring a brighter future for patients and communities alike. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. * Includes one facility via PPL's minority investment in Yapan Bio.
